Clinical trials: Vehicle, completed
Genital Warts
Study of Imiquimod Cream Prior to Ablative Therapy in External Ano-Genital Warts
The purpose of this study is to compare the recurrence rate following total clearance of external genital warts (EGWs) when clearance has been obtained by imiquimod (3 applications per week for 4 weeks) followed by ablative…
- Trial name
- NCT00189293
- Testing
- Imiquimod, vehicle cream
- Where
- 12 sites in Italy
- Volunteers
- 128 people
- Sponsor
- MEDA Pharma GmbH & Co. KG
Actinic Keratosis
Evaluation of Two Different Non-invasive Techniques to Monitor the Clearance of Actinic Keratosis Lesions
The purpose of this study is to evaluate the performance of two techniques to monitor the clearance of AK lesions when treated with Aldara 5% cream.
- Trial name
- NCT00294320
- Testing
- Aldara (Imiquimod), Vehicle cream
- Where
- France
- Volunteers
- 12 people
- Sponsor
- MEDA Pharma GmbH & Co. KG
Healthy Volunteers
A Study to Evaluate the Skin Irritation Potential of PBI-100 Topical Cream in Healthy Participants
This is an open-label, single-arm, randomized, evaluator-blinded repeat insult patch testing (RIPT) study wherein test product is applied under an occlusive dressing to the upper back or arm continuously and repeatedly to the…
- Trial name
- NCT04882631
- Testing
- PBI-100 Topical Cream, Positive Control - Sodium laurel sulfate (SLS), PBI-100 Topical Cream, Vehicle
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Pyramid Biosciences
Pain, Acute
Controlled Study to Assess the Efficacy and Safety of S-Ibuprofen Topical Gel 5% (AP0302) in the Treatment of DOMS
Phase 2 study designed to evaluated analgesic efficacy and safety of S-Ibuprofen Topical Gel 5%
- Trial name
- NCT03852459
- Testing
- S-Ibuprofen, Vehicle
- Where
- United States
- Volunteers
- 251 people, healthy volunteers welcome
- Sponsor
- Aponia Laboratories, Inc.
Dry Eye Syndrome
Study of SkQ1 as Treatment for Dry-eye Syndrome
The purpose of this study is to evaluate whether SkQ1 ophthalmic solutions are safe and effective compared to placebo for the treatment of the signs and symptoms of dry eye syndrome.
- Trial name
- VISTA-1 (NCT03764735)
- Testing
- Low Dose - SkQ1, High dose - SkQ1, SkQ1 (Vehicle)
- Where
- 7 sites in United States
- Volunteers
- 452 people
- Sponsor
- Mitotech, SA
Dry Eye Syndrome
Vehicle-Controlled Study of SkQ1 as Treatment for Dry-eye Syndrome
The purpose of this study is to evaluate whether SkQ1 Ophthalmic Solution is safe and effective compared to Vehicle for the treatment of the signs and symptoms of dry eye syndrome.
- Trial name
- VISTA-2 (NCT04206020)
- Testing
- SkQ1 Vehicle Solution, SkQ1 Ophthalmic Solution
- Where
- 4 sites in United States
- Volunteers
- 610 people
- Sponsor
- Mitotech, SA
Pain, Acute, Itch
The Effect of Halophyte-based Cream on Pain and Itch
In this study the investigators wish to investigate whether halophyte-based cream applied to the skin can reduce itch applied by means of small needles from the plant mucuna pruriens (also called cowhage) or by histamine (an…
- Trial name
- NCT04635254
- Testing
- Halophites-based cream 24 hours, Halophites-based cream 48 hours, Vehicle cream 24 hours
- Where
- Denmark
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Aalborg University
Acne Vulgaris
A Study to Compare the Efficacy and Safety of Topical Administration of FMX-101 for Treatment of Moderate-to-Severe Acne
This is a Phase 3 study to evaluate the efficacy, safety and long-term safety of the topical administration of FMX-101, 4% minocycline foam for the treatment of moderate-to-severe acne vulgaris.
- Trial name
- NCT02815267
- Testing
- FMX-101, 4% minocycline foam, Vehicle Foam
- Where
- 31 sites in United States, Dominican Republic
- Volunteers
- 466 people
- Sponsor
- Vyne Therapeutics Inc.
Acne Vulgaris
A Study to Compare the Efficacy and Safety of Topical Administration of FMX-101 for Treatment of Moderate-to-Severe Acne
This is a Phase 3 study to evaluate the efficacy, safety and long-term safety of the topical administration of FMX-101, 4% minocycline foam for the treatment of moderate-to-severe acne vulgaris.
- Trial name
- NCT02815280
- Testing
- FMX-101, 4% minocycline foam, Vehicle Foam
- Where
- 36 sites in United States, Dominican Republic
- Volunteers
- 495 people
- Sponsor
- Vyne Therapeutics Inc.
Acne Vulgaris
A Study to Evaluate the Efficacy and Safety of Topical Administration of FMX101 in the Treatment of Moderate-to-Severe Acne Vulgaris
A Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Efficacy and Safety of Topical Administration of FMX101 for 12 Weeks in the Treatment of Moderate-to-Severe Acne Vulgaris (Study FX2017-22)
- Trial name
- NCT03271021
- Testing
- FMX101, Vehicle Foam
- Where
- 98 sites in United States
- Volunteers
- 1,488 people
- Sponsor
- Vyne Therapeutics Inc.
Dry Eye Disease
Efficacy of OC-01 Nasal Spray on Goblet Cell and Meibomian Gland Stimulation
The objective of this study is to evaluate the safety and effectiveness of OC-01 Nasal Spray as compared to placebo in simulating Goblet Cell and Meibomian Gland function in adult subjects with DED.
- Trial name
- NCT03688802
- Testing
- OC-01 (varenicline) nasal spray
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Oyster Point Pharma, Inc.
Presbyopia
A Phase 3 Efficacy Study of Pilocarpine HCl Ophthalmic Solution (AGN-190584) in Participants With Presbyopia
This clinical study will evaluate pilocarpine hydrogen chloride (HCl) ophthalmic solution (AGN-190584) in an expanded participant population to establish efficacy, safety, and tolerability versus the vehicle-control when…
- Trial name
- GEMINI 2 (NCT03857542)
- Testing
- Pilocarpine HCl Ophthalmic Solution, Vehicle
- Where
- 35 sites in United States
- Volunteers
- 427 people
- Sponsor
- Allergan
Presbyopia
Efficacy Study of Pilocarpine HCl Ophthalmic Solution (AGN-190584) in Participants With Presbyopia
A study to evaluate the efficacy, safety, and pharmacokinetics of pilocarpine hydrochloride (HCl) ophthalmic solution (AGN-190584) when administered bilaterally, once daily for 30 days in participants with presbyopia.
- Trial name
- GEMINI 1 (NCT03804268)
- Testing
- Vehicle, Pilocarpine HCl Ophthalmic Solution
- Where
- 36 sites in United States
- Volunteers
- 323 people
- Sponsor
- Allergan
Acne Vulgaris
A Study of S6G5T-3 in the Treatment of Acne Vulgaris
To assess the efficacy of S6G5T-3 compared to its Vehicle when applied once daily for 12 weeks in participants with acne vulgaris.
- Trial name
- NCT03761784
- Testing
- S6G5T-3, S6G5T-8
- Where
- United States
- Volunteers
- 424 people
- Sponsor
- Sol-Gel Technologies, Ltd.
Acne Vulgaris
A Study of S6G5T3 in the Treatment of Acne Vulgaris
To assess the efficacy of S6G5T-3 compared to its vehicle when applied once daily for 12 weeks in participants with acne vulgaris.
- Trial name
- NCT03761810
- Testing
- S6G5T-3, S6G5T-8
- Where
- United States
- Volunteers
- 434 people
- Sponsor
- Sol-Gel Technologies, Ltd.
Papulopustular Rosacea
A Study of S5G4T-1 in the Treatment of Papularpustular Rosacea
To assess the efficacy and safety of S5G4T-1 compared to S5G4T-1 vehicle when applied once daily for 12 weeks in participants with papulopustular rosacea.
- Trial name
- NCT03564119
- Testing
- S5G4T-1, S5G4T-2
- Where
- United States
- Volunteers
- 372 people
- Sponsor
- Sol-Gel Technologies, Ltd.
Conjunctivitis, Vernal
Efficacy and Tolerance of Nova22007 Versus Vehicle in Patients With Vernal Keratoconjunctivitis (VKC)
The primary objective of this study is: To assess the efficacy of Nova22007, a cyclosporine A (CsA), 0.05% and 0.1% versus vehicle in patients with vernal keratoconjunctivitis (VKC) after a 4-week treatment period.
- Trial name
- NCT00328653
- Testing
- Cyclosporine NOVA22007 0.05%, Cyclosporine NOVA22007 0.1%, Vehicle
- Where
- France
- Volunteers
- 118 people
- Sponsor
- Santen SAS
Papulopustular Rosacea
A Study of S5G4T-1 in the Treatment of Papulopustular Rosacea
To assess the efficacy and safety of S5G4T-1 compared to its vehicle when applied once daily for 12 weeks in participants with papulopustular rosacea.
- Trial name
- NCT03448939
- Testing
- S5G4T-1, S5G4T-2
- Where
- United States
- Volunteers
- 361 people
- Sponsor
- Sol-Gel Technologies, Ltd.
Dry Eye Disease
Clinical Trial to Evaluate the Efficacy of OC-02 Nasal Spray on Signs and Symptoms of Dry Eye Disease (The PEARL Study)
The objective of this study is to evaluate the safety and effectiveness of OC-02 Nasal Spray as compared to placebo on signs and symptoms of dry eye disease.
- Trial name
- NCT03452397
- Testing
- 0.2 % hemigalactarate (0.11% free base) 0.2 % OC-02 Low Dose (1.1 mg/mL), 1.0 % hemigalactarate (0.11% free base) 1.0 % OC-02 Mid Dose (5.5 mg/mL), 2.0 % hemigalactarate (0.11% free base) 2.0 % OC-02 High Dose (11.1 mg/mL)
- Where
- 3 sites in United States
- Volunteers
- 165 people
- Sponsor
- Oyster Point Pharma, Inc.
Dry Eye Syndrome, Keratoconjunctivitis Sicca
Dose Ranging Study to Assess the Efficacy and Safety of Voclosporin Ophthalmic Solution in Subjects With Dry Eye Syndrome
A Multi-Center, Phase 2/3, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Clinical Trial to Assess the Safety and Efficacy of Voclosporin Ophthalmic Solution (0.05%, 0.10%, 0.20%) Compared to Vehicle in Subjects…
- Trial name
- AUDREY (NCT04147650)
- Testing
- 0.05% Voclosporin Ophthalmic Solution (VOS), 0.10% VOS, 0.20% VOS
- Where
- 9 sites in United States
- Volunteers
- 508 people
- Sponsor
- Aurinia Pharmaceuticals Inc.